ArticleBMC cancer2026

NAV-005, a high-affinity MUC16/CA125 antagonist for the treatment of humoral immunosuppressed cancers.

Nicholas C Nicolaides et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.